IRADIMED vs. Artivion: Valuation Gap Widens
IRADIMED's New 3870 Pump Drives Q2 Growth Despite Margin Pressures, Widening Artivion Valuation Gap
Anonymous
Key Points
1
Insider ownership is notably higher at iRadimed than Artivion, with iRadimed having 34.6% insiders versus Artivion's 6.3%. This contrasts with the broader institutional ownership levels (iRadimed 92.3% vs Artivion 86.4%), suggesting different governance dynamics and potential implications for future capital allocation.
2
iRadimed produced more than 130 units of its new 3870 MRI IV pump in Q2 2026, meeting its target of 130–135 units, and bookings for the 3870 exceeded shipments by more than two-fold, signaling strong initial demand and replacement opportunities.
3
U.S. replacement opportunities are substantial, with about 6,400 older 3860/3861 pump channels in the U.S. eligible for replacement; 70% of older two-channel systems were replaced with quad four-channel pumps, which carry ASPs above $110,000 and have driven more than a 20% uplift in average selling price per pump.
4
Gross margin declined to 74% in Q2 2026 from 78% due to initial production inefficiencies tied to ramping the 3870 pump, while revenue grew modestly and geographic mix shifted as U.S. sales fell 8% year over year and international sales rose 69%.
5
iRadimed projected Q3 2026 production of more than 300 units of the 3870 pump, indicating continued ramp-up and scale-up plans for the new system beyond Q2 results.
iRadimed's valuation gap with rival Artivion is widening, even as both small-cap healthcare stocks attract strong institutional backing. iRadimed posted Q2 2026 revenue of $20.47 million — roughly flat year-over-year — while net income came in at $5.22 million, or $0.41 per diluted share, according to TradingView. The results reflect early growing pains from ramping up its new 3870 MRI IV pump system.
Despite the margin squeeze, iRadimed raised its full-year 2026 EPS guidance to a range of $2.09–$2.24, well above the Wall Street consensus of $1.96, per Watchlist News. The stock carries a beta of roughly 0.9, making it less volatile than Artivion's 1.26. Artivion, by contrast, commands a higher analyst upside target but comes with more risk.
New 3870 Pump Ramp Squeezes Gross Margins
Gross margin fell to 74% in Q2 2026, down from 78% a year earlier. The culprit was the initial production ramp of the 3870 MRI IV pump — a new system that brought higher labor and overhead costs before the line hit full efficiency. TradingView noted the margin drag was tied directly to new-product manufacturing inefficiencies.
Despite the margin hit, iRadimed produced more than 130 units of the 3870 in Q2, hitting its target range of 130–135 units. Bookings for the new pump outpaced shipments by more than two-to-one, signaling strong early demand. Management projects Q3 output to exceed 300 units — more than double Q2 — as the production line scales up, per Watchlist News.
6,400 Older Pump Channels Ready for Replacement
The 3870 system targets a large and waiting U.S. replacement market. About 6,400 older two-channel pump channels — more than five years old — are eligible for an upgrade. iRadimed plans to replace roughly 1,000 channels per year. Around 70% of customers swapping out older two-channel systems choose the new quad four-channel pumps.
Those quad upgrades carry average selling prices above $110,000 and have pushed iRadimed's average selling price per pump up by more than 20%. That pricing power is a key reason analysts see a path to stronger revenue even if unit volumes grow modestly. The replacement runway is deep, and most of the eligible installed base has yet to be touched.
International Sales Surge as U.S. Revenue Slips
The geographic mix shifted sharply in Q2. U.S. sales fell 8% year-over-year, while international sales jumped 69%. That pushed the domestic share of revenue from 89% to 82%. TradingView reported the overall top line stayed nearly flat as international strength offset weakness at home.
iRadimed also declared a quarterly dividend of $0.20 per share, yielding about 0.9%. Insider ownership stands at 34.6%, far above Artivion's 6.3%, per Ticker Report. Institutional ownership is 92.3% at iRadimed versus 86.4% at Artivion. The CEO has made some stock sales, but the concentrated insider stake signals long-term alignment with shareholders.
Guidance Beat Points to Stronger Second Half
For Q3 2026, iRadimed guided EPS to $0.54–$0.59, compared to a consensus estimate that was lower, according to Watchlist News. The updated full-year EPS range of $2.09–$2.24 also tops the $1.96 consensus. Management cited robust bookings and replacement demand as drivers for the stronger outlook.
The key question is how fast margins recover as the 3870 production line matures. If the Q3 target of 300-plus units is met, fixed costs spread over more units should lift margins back toward prior levels. iRadimed's lower valuation multiple, compared to Artivion, may look more attractive if that margin recovery materializes in the back half of 2026.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
17
Articles
50
Reach
67
A
AnonymousAuthor